• Post category:Blog
  • Post comments:0 Comments
  • Reading time:7 mins read

TENLIFAST-M 1000 SR – Uses, MOA, Benefits, and Recommended Dosage

TENLIFAST-M 1000 SR

Introduction:

TENLIFAST-M 1000 SR, a groundbreaking creation by Invision Medi Sciences, synergizes Teneligliptin Hydrobromide Hydrate (20 mg) and Extended-Release Metformin Hydrochloride (1000 mg). This guide explores the uses, benefits, recommended dosage, and the dynamic interplay of TENLIFAST-M 1000 SR, revolutionizing diabetes care.

Teneligliptin and Extended-Release Metformin: A Unified Front Against Diabetes:

TENLIFAST-M 1000 SR features the potent combination of Teneligliptin and Extended-Release Metformin, offering a unified approach to combatting diabetes. Teneligliptin enhances insulin secretion, while Extended-Release Metformin addresses insulin resistance, ensuring comprehensive glycemic control.

Indications for TENLIFAST-M 1000 SR:

  1. Advanced Type 2 Diabetes Management: TENLIFAST-M 1000 SR is indicated for individuals requiring advanced glycemic control.
  2. Long-Lasting Relief: The extended-release formulation ensures sustained drug release for optimal diabetes management.

Benefits of TENLIFAST-M 1000 SR:

  1. Dual Action: Teneligliptin and Extended-Release Metformin work synergistically, tackling key aspects of diabetes pathophysiology for comprehensive management.
  2. Convenient Once-Daily Dosing: The extended-release formulation allows for a once-daily dosage, promoting patient adherence.

Recommended Dosage:

Healthcare providers tailor the dosage of TENLIFAST-M 1000 SR to individual health needs. Consistent adherence to the prescribed dosage is vital for optimal glycemic control.

Potential Side Effects:

While generally well-tolerated, some individuals may experience mild side effects:

  • Gastrointestinal Distress: Occasional gastrointestinal discomfort may occur.
  • Blood Glucose Monitoring: Regular monitoring is crucial to prevent hypoglycemia.

Essential Information:

  1. Patient Education: Patients are educated on recognizing and managing hypoglycemic symptoms for proactive care.
  2. Comprehensive Diabetes Care: TENLIFAST-M 1000 SR represents Invision Medi Sciences’ commitment to providing advanced solutions for diabetes management.

Conclusion:

TENLIFAST-M 1000 SR, enriched with Teneligliptin and Extended-Release Metformin, exemplifies Invision Medi Sciences’ dedication to advancing diabetes care. Its dual-action formula addresses the intricacies of diabetes, ensuring optimal glycemic control.

Related Combinations:

  1. Tenlifast-M 500SR: Elevating care with Teneligliptin and Extended-Release Metformin.
  2. Tenlifast-20: Redefining precision in glycemic control with the efficacy of Teneligliptin 20 mg tablets.

Discover the synergy of our diabetes care offerings at Invision Medi Sciences.

TENLIFAST-M 1000 SR: Transforming diabetes care with the harmonious blend of Teneligliptin and Extended-Release Metformin.

FAQs


How does TENLIFAST-M 1000 SR differ from other diabetes medications?

TENLIFAST-M 1000 SR offers advanced glycemic control through the synergistic action of Teneligliptin and Extended-Release Metformin in a convenient once-daily formulation.

Is TENLIFAST-M 1000 SR suitable for individuals with insulin resistance?

Yes, TENLIFAST-M 1000 SR is indicated for individuals requiring advanced glycemic control, addressing both insulin secretion and resistance.

Can hypoglycemia occur with TENLIFAST-M 1000 SR?

Monitoring blood glucose levels is crucial to prevent hypoglycemia. Patients are educated on recognizing and managing hypoglycemic symptoms.

Is there a specific time to take TENLIFAST-M 1000 SR?

TENLIFAST-M 1000 SR is preferably taken with meals. Healthcare providers provide individualized guidance on the timing of dosages.

Can TENLIFAST-M 1000 SR be used as a standalone treatment for diabetes?

TENLIFAST-M 1000 SR is suitable for advanced diabetes management. Healthcare providers may prescribe it as part of a comprehensive treatment plan.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.